Pirsue
Authorised
This medicine is authorised for use in the European Union
pirlimycin
MedicineVeterinaryAuthorised
Overview
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Pirsue is an antibiotic that contains pirlimycin hydrochloride as the active substance. It is given to dairy cows by infusion into the udder via the teat canal using a prefilled syringe.
Pirsue is used in dairy cows to treat sub-clinical mastitis caused by specific groups of bacteria. Mastitis is an infection in the udder. Sub-clinical means that the infection is present but not sufficiently developed to produce clear clinical signs in the cow. Since milk is routinely checked for bacteria and other signs of infection, early stages of an udder infection in a dairy cow can easily be diagnosed. Pirsue is given into each infected teat of the udder for eight consecutive days.
The active substance in Pirsue is pirlimycin hydrochloride, an antibiotic of the lincosamide group. It works by blocking the bacteria’s ribosomes. This is the part of the cell where proteins are produced. As a result, the bacteria cannot produce any more protein and will stop growing.
Information was provided on the pharmaceutical quality, the tolerance of the product in cows and the safety in humans (people in contact with the product and consumers of meat and milk) and the environment.
The antimicrobial effectiveness of pirlimycin against different groups of bacteria causing disease in dairy cows was investigated in microbiological laboratories. In these studies, the effective concentration of pirlimycin required to stop bacterial growth was established.
Clinical effectiveness was studied in a large number of dairy herds in eight European countries. Cows with sub-clinically infected udders were treated with Pirsue (once daily for eight days) or with another antibiotic authorised in the European Union (EU) to treat these infections. Milk samples were checked daily up to 30 days after treatment for bacteria and for other signs of infection.
The results of these studies showed that Pirsue is effective at inhibiting the bacterial growth of a range of bacteria. The field trial showed that treatment with Pirsue at the recommended dose was effective in the treatment of sub-clinical udder infections.
Pirsue is generally well tolerated in cows.
However, in rare cases, serious bacterial udder infections have occurred after treatment. These infections were caused by incorrect administration of the product by the operator who, by inserting the syringe without adequate cleansing procedures, also inserted pathogenic (disease-causing) bacteria from the environment into the udder. Special care must therefore be taken by the operator not to introduce pathogens into the teat. Both the teat and the udder should be adequately cleansed and the teat end disinfected before using Pirsue.
Pirlimycin hydrochloride can cause severe eye and skin irritation.
Care should therefore be taken by the user of the product to avoid contact with the solution. Skin that has been in contact with Pirsue should be washed and eyes should be flushed with water for 15 minutes immediately after exposure.
After the last day of treatment with Pirsue, treated cows should not be slaughtered for 23 days.
After the last day of treatment with Pirsue, milk from treated cows should not be used for five days.
The CVMP concluded that the benefits of Pirsue exceed the risks for the treatment of subclinical mastitis in lactating cows and recommended that Pirsue be given a marketing authorisation. The benefit-risk balance may be found in module 6 of this EPAR.
The European Commission granted a marketing authorisation valid throughout the European Union for Pirsue on 29 January 2001. The authorisation was renewed on 29 January 2006. Information on the prescription status of this product may be found on the label / outer package.
Product information
Latest procedure affecting product information: IB/0027/G
18/06/2021
Product details
- Name of medicine
- Pirsue
- Active substance
- pirlimycin
- International non-proprietary name (INN) or common name
- pirlimycin
- Species
- Cattle
- Anatomical therapeutic chemical veterinary (ATCvet) code
- QJ51FF90
Pharmacotherapeutic group
Antibacterials for intramammary useTherapeutic indication
For the treatment of subclinical mastitis in lactating cows due to Gram-positive cocci susceptible to pirlimycin including staphylococcal organisms such as Staphylococcus aureus, both penicillinase-positive and penicillinase-negative, and coagulase-negative staphylococci; streptococcal organisms including Streptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus uberis.
News on Pirsue
Topics
This page was last updated on